Atea announces first patient dosed in Phase 2 study of bemnifosbuvir, ruzasvir

Atea Pharmaceuticals announced the dosing of the first patient in the Phase 2 bemnifosbuvir and ruzasvir combination study for the treatment of Hepatitis C Virus infection. “The initiation of this Phase 2 combination study marks an important clinical milestone for Atea,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. “We believe the combination of bemnifosbuvir and ruzasvir has the potential to significantly improve upon the current standard of care by offering a short duration, pan-genotypic, protease inhibitor-free treatment for patients with HCV, with or without cirrhosis.”